Recital 5, Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…

In forcesince 6 May 2009cited 24×

This situation leads to a lack of protection which penalises pharmaceutical research.

The 10 that are cited most themselves, of 24.

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Medeva BV v Comptroller General of Patents, Designs and Trade Marks.Decision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: ‘(1) Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal …

    24 Nov 2011 · 62010CJ0322

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Georgetown University and Others v Comptroller General of Patents, Designs and TDecision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products …

    24 Nov 2011 · 62010CJ0422

  • Judgment of the Court (Third Chamber), 12 December 2013. Actavis Group PTC EHF and Actavis UK Ltd v Sanofi.Decision

    Recitals 4, 5, 9 and 10 in the preamble to Regulation No 469/2009 read as follows: At the moment, the period that elapses between the filing of an application for a patent for a new medicinal product and authorisation to place the …

    12 Dec 2013 · 62012CJ0443

  • Judgment of the Court (Fourth Chamber), 19 July 2012. Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.Decision

    Recitals 1 and 4 to 10 of the SPC Regulation read as follows: Council Regulation (EEC) No 1768/92 … has been substantially amended several times. In the interests of clarity and rationality the said Regulation should be codified. ... At …

    19 Jul 2012 · 62011CJ0130

  • Judgment of the Court (Eighth Chamber) of 12 March 2015. Actavis Group PTC EHF and Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. KDecision

    Recitals 4, 5, 9 and 10 in the preamble to Regulation No 469/2009 are worded as follows: At the moment, the period that elapses between the filing of an application for a patent for a new medicinal product and authorisation to place the …

    12 Mar 2015 · 62013CJ0577

  • Order of the Court (Fourth Chamber) of 25 November 2011. University of Queensland and CSL Ltd v Comptroller General of Patents, Designs and Decision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: ‘(1) Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal …

    25 Nov 2011 · 62010CO0630

  • Judgment of the Court (Grand Chamber) of 25 July 2018. Teva UK Ltd and Others v Gilead Sciences Inc.Decision

    It must be added that, in view of the interests referred to in recitals 4, 5, 9 and 10 of Directive 469/2009, it cannot be accepted that the holder of a basic patent in force may obtain an SPC each time he places on the market in a Member …

    25 Jul 2018 · 62017CJ0121

  • Judgment of the Court (Third Chamber), 12 December 2013. Georgetown University v Octrooicentrum Nederland.Decision

    Recitals 4, 5, 9 and 10 in the preamble to Regulation No 469/2009 read as follows: At the moment, the period that elapses between the filing of an application for a patent for a new medicinal product and authorisation to place the …

    12 Dec 2013 · 62012CJ0484

  • Order of the Court (Fourth Chamber) of 25 November 2011. Daiichi Sankyo Company v Comptroller General of Patents, Designs and Trade Marks.Decision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products …

    25 Nov 2011 · 62011CO0006

  • Judgment of the Court (Fourth Chamber) of 21 March 2019. Abraxis Bioscience LLC v Comptroller General of Patents.Decision

    Recitals 3 to 5 and 7 to 10 of Regulation No 469/2009 state as follows: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the [European Union] and in Europe unless they …

    21 Mar 2019 · 62017CJ0443